Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Syngenta's $9.5 billion IPO moves closer with Shanghai bourse hearing

Published 03/22/2023, 03:15 AM
Updated 03/22/2023, 09:05 AM
© Reuters. FILE PHOTO: A logo is seen at the headquarters of agricultural chemical maker Syngenta in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann

By John Revill and Julie Zhu

ZURICH/HONG KONG (Reuters) - Syngenta's $9.5 billion flotation has moved a step closer after the Shanghai Stock Exchange scheduled a hearing next week for the Swiss agrichemicals and seeds company's listing plan.

A rival to U.S. company Corteva (NYSE:CTVA) and German firms BASF and Bayer (OTC:BAYRY), Syngenta was bought for $43 billion by ChemChina in 2017 and folded into Sinochem Holdings Corp in 2021.

The Chinese parent plans to keep a majority stake after the initial public offering (IPO), which is set to be one of the world's biggest this year and expected to value Syngenta at around $50 billion.

The Shanghai Stock Exchange said on Wednesday it planned to conduct a hearing with the company to examine its listing application on March 29. Syngenta has also updated its prospectus with its latest financial figures.

It shows the company aims to raise about 65 billion yuan from the flotation or about $9.44 billion. 

Just over 60% of the proceeds will be used to finance acquisitions and to repay debt.

Around 20% will be allocated towards advanced agricultural technology-related research and development, according to the prospectus.

After Syngenta passes the hearing, the IPO will still require registration with the China Securities Regulatory Commission.

The company aims to launch the offering in June, two sources said, with one adding that it is seeking mainly Chinese investors as strategic shareholders. 

Syngenta declined to comment, citing Chinese market regulations.

The float will likely be the four-year-old STAR board's biggest - providing a major boost after the scrapping of Ant Group's blockbuster listing in 2020.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The Nasdaq-style STAR Market topped the global charts for IPO fundraising in 2022 having raised $28.5 billion, Refinitiv Eikon data showed.

Syngenta first filed its listing application in July 2021 and has since gone through three rounds of reviews with the Shanghai bourse.

The company reported its highest ever annual sales and earnings on Wednesday. Its 2022 earnings before interest, tax, depreciation and amortisation (EBITDA) rose 20% to $5.6 billion on sales up 19% at $33.4 billion.

Much of the growth came from China, where the company added 136 more Modern Agricultural Platform centres that offer training to farmers and sell its seeds and pesticides, taking its total there to 628.

"All business units saw double-digit growth, benefitting from high demand for products and services designed to promote yield increases and sustainable farming methods," Syngenta said.

But during the fourth quarter, its earnings fell after being hit by higher raw materials costs. It also spent more on reorganising its business and set cash aside to cover macro-economic uncertainties.

Its EBITDA fell 25% to $900 million on sales up 4% to $7.5 billion driven by its seeds business.

"As previously indicated, farmers accelerated their purchases earlier in the year due to supply concerns, moderating fourth quarter growth," the company said.

($1 = 6.8830 Chinese yuan renminbi)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.